{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:52:00Z","timestamp":1786996320395,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T00:00:00Z","timestamp":1496793600000},"content-version":"vor","delay-in-days":157,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","respiratorycasereports.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine Case Reports"],"published-print":{"date-parts":[[2017]]},"DOI":"10.1016\/j.rmcr.2017.07.007","type":"journal-article","created":{"date-parts":[[2017,7,15]],"date-time":"2017-07-15T15:50:50Z","timestamp":1500133850000},"page":"109-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Scleroderma-related interstitial lung disease"],"prefix":"10.1016","volume":"22","author":[{"given":"Sally","family":"Suliman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdalhamid","family":"Al Harash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Neil","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael L.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmcr.2017.07.007_bib1","doi-asserted-by":"crossref","DOI":"10.1007\/s00296-016-3636-7","article-title":"Interstitial lung disease in systemic sclerosis: current and future treatment","author":"Giacomelli","year":"2017","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.rmcr.2017.07.007_bib2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/0003-4819-57-2-305","article-title":"A\u00a0historical account of the study of progressive systemic sclerosis (diffuse scleroderma)","volume":"57","author":"Rodnan","year":"1962","journal-title":"Ann. Intern Med."},{"key":"10.1016\/j.rmcr.2017.07.007_bib3","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3899\/jrheum.111106","article-title":"Epidemiology of systemic sclerosis in a large US managed care population","volume":"39","author":"Furst","year":"2012","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.rmcr.2017.07.007_bib4","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A\u00a0multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rmcr.2017.07.007_bib5","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.autrev.2016.07.025","article-title":"Pulmonary involvement in systemic sclerosis","volume":"15","author":"Morales-Cardena","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.rmcr.2017.07.007_bib6","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.rmcr.2017.07.007_bib7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1183\/09031936.00060209","article-title":"Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases","volume":"35","author":"Gilson","year":"2010","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmcr.2017.07.007_bib8","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.autrev.2016.07.025","article-title":"Pulmonary involvement in systemic sclerosis","volume":"15","author":"Morales-Cardenas","year":"2016","journal-title":"Autoimmune Rev."},{"key":"10.1016\/j.rmcr.2017.07.007_bib9","first-page":"244","article-title":"Risk factors associated with pulmonary arterial hypertension in Colombian patients with systemic sclerosis: review of the literature","volume":"35","author":"Coral-Alvarado","year":"2008","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.rmcr.2017.07.007_bib10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1183\/09059180.00005512","article-title":"Scleroderma lung disease","volume":"22","author":"Solomon","year":"2013","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.rmcr.2017.07.007_bib11","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Scleroderma Lung Study Research G. Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.rmcr.2017.07.007_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1517\/21678707.2016.1114454","article-title":"Treatment of rapidly progressive systemic sclerosis: current and futures perspectives","volume":"4","author":"Mendoza","year":"2016","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.rmcr.2017.07.007_bib13","doi-asserted-by":"crossref","first-page":"e0124205","DOI":"10.1371\/journal.pone.0124205","article-title":"Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review","volume":"10","author":"Omair","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.rmcr.2017.07.007_bib14","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/1756-185X.12399","article-title":"Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series","volume":"17","author":"Yilmaz","year":"2014","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.rmcr.2017.07.007_bib15","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Sclerodema Lung Study III. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmcr.2017.07.007_bib16","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/S2213-2600(16)30318-6","article-title":"Mycophenolate mofetil for scleroderma-related interstitial lung disease","volume":"4","author":"Zaheen","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmcr.2017.07.007_bib17","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.rmcr.2017.07.007_bib18","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.bbadis.2012.12.007","article-title":"Strategies for anti-fibrotic therapies","volume":"1832","author":"Rosenbloom","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.rmcr.2017.07.007_bib19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1517\/13543784.2014.848852","article-title":"Novel investigational agents for the treatment of scleroderma","volume":"23","author":"McMahan","year":"2014","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.rmcr.2017.07.007_bib20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.rdc.2015.04.004","article-title":"Management of systemic sclerosis-related skin disease: a review of existing and experimental therapeutic approaches","volume":"41","author":"Volkmann","year":"2015","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/j.rmcr.2017.07.007_bib21","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.2174\/0929867322666150209161224","article-title":"Molecular and cellular pathways as treatment targets for biologic therapies in systemic sclerosis","volume":"22","author":"Dimitroulas","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.rmcr.2017.07.007_bib22","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.rmcr.2017.07.007_bib23","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.rmcr.2017.07.007_bib24","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1164\/rccm.2106012","article-title":"Histopathological subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome","volume":"165","author":"Bouros","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmcr.2017.07.007_bib25","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.151322","article-title":"An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS Trial","volume":"43","author":"Khanna","year":"2016","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.rmcr.2017.07.007_bib26","first-page":"235","article-title":"Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease","volume":"31","author":"Miura","year":"2014","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.rmcr.2017.07.007_bib27","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.4049\/jimmunol.0803705","article-title":"Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse","volume":"182","author":"Servettaz","year":"2009","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.rmcr.2017.07.007_bib28","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/art.27549","article-title":"Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I\/III antibodies","volume":"62","author":"Shah","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rmcr.2017.07.007_bib29","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/BOR.0b013e32834a5081","article-title":"Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications","volume":"23","author":"Shah","year":"2011","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.rmcr.2017.07.007_bib30","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/art.39022","article-title":"Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma","volume":"67","author":"Shah","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.rmcr.2017.07.007_bib31","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/BOR.0000000000000222","article-title":"Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening","volume":"27","author":"Shah","year":"2015","journal-title":"Curr. Opin. Rheumatol."}],"container-title":["Respiratory Medicine Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007117301557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007117301557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T01:53:22Z","timestamp":1535594002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213007117301557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":31,"alternative-id":["S2213007117301557"],"URL":"https:\/\/doi.org\/10.1016\/j.rmcr.2017.07.007","relation":{},"ISSN":["2213-0071"],"issn-type":[{"value":"2213-0071","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Scleroderma-related interstitial lung disease","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmcr.2017.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}